Form 4: Keros Therapeutics Director Receives Equity Grant

Director Mary Ann Gray acquired 7,142 restricted stock units and 7,433 stock options in Keros Therapeutics.

Summary

• Director Mary Ann Gray was granted 7,142 restricted stock units (RSUs) on June 3, 2026.
• The director also received a stock option grant for 7,433 shares with an exercise price of $10.50.
• The RSU award vests on the earlier of June 3, 2027, or the date of the 2027 annual meeting.
• The stock options vest in equal quarterly installments over 12 months, fully vesting by the 2027 annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Equity-based compensation aligns the director's interests with long-term shareholder value.
• The grants are subject to continued service requirements, promoting retention.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future share price volatility may impact the ultimate value of the granted equity.
• Continued service requirements create a dependency on the director's ongoing tenure.

Future Outlook

The equity grants are structured to vest over the next 12 months, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that standard equity compensation for board members in the biotechnology sector is a common practice to ensure alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of RSUs and stock options is consistent with standard compensation packages for non-employee directors in mid-cap biotech firms.
• Vesting schedules tied to annual meetings are standard corporate governance practices.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of RSUs on June 3, 2027 or the 2027 annual meeting.
• Quarterly vesting of stock options over the next 12 months.

Key Dates

Keywords

Keros Therapeutics, KROS, Form 4, Insider Trading, Equity Compensation, Director Compensation